// App-Quantinova.ai

: Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.

Researchers

Presenter

  • Nizar M. Tannir

Principal Investigators

  • Elizabeth R. Plimack

  • David F. McDermott

  • Philippe Barthelemy

  • Camillo Porta

  • Saby George

  • Thomas Powles

  • Frede Donskov

  • Christian K. Kollmannsberger

  • Howard Gurney

  • Asim Amin

  • Marc-Oliver Grimm

  • Brian I. Rini

  • Yoshihiko Tomita

  • M. Brent McHenry

  • Sabeen Fatima Mekan

  • Bernard Escudier

  • Hans J. Hammers

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Fox Chase Cancer Center, Philadelphia, PA

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Medical Oncology, Hopitaux Universitaires de Strasbourg, Strasbourg, France

  • University of Pavia, Pavia, Italy

  • Roswell Park Cancer Institute, Buffalo, NY

  • Barts Cancer Institute, Royal Free NHS trust, St. Bartholomew’s Hospital, London, United Kingdom

  • Aarhus University Hospital, Aarhus, Denmark

  • The University of British Columbia, Vancouver, BC, Canada

  • Westmead Hospital and Macquarie University, Sydney, Australia

  • Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Niigata University, Niigata, Japan

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Monter Cancer Ctr, New York, NY

  • Gustave Roussy, Villejuif, France

  • UT Southwestern, Dallas, TX

Locations

  • United States

  • France

  • Italy

  • United Kingdom

  • Denmark

  • Canada

  • Australia

  • Germany

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

  • Sunitinib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT02231749

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved